{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T01:18:37Z","timestamp":1782436717759,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12325-025-03110-0","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T07:48:23Z","timestamp":1741247303000},"page":"2019-2039","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Recombinant Factor\u00a0VIII in Previously Untreated and Previously Treated Children with Hemophilia\u00a0A: A Systematic Review"],"prefix":"10.1007","volume":"42","author":[{"given":"Xiaoqin","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenguo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"issue":"30","key":"3110_CR1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2023.38.e235","volume":"38","author":"YB Choi","year":"2023","unstructured":"Choi YB, Shim YJ, Kim SG, Lee WK. Complication analysis in Korean patients with hemophilia\u00a0A from 2007 to 2019: a nationwide study by the health insurance review and assessment service database. J Korean Med Sci. 2023;38(30):e235.","journal-title":"J Korean Med Sci"},{"issue":"8","key":"3110_CR2","doi-asserted-by":"publisher","first-page":"540","DOI":"10.7326\/M19-1208","volume":"171","author":"A Iorio","year":"2019","unstructured":"Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540\u20136.","journal-title":"Ann Intern Med"},{"issue":"11","key":"3110_CR3","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1016\/j.jtha.2023.05.011","volume":"21","author":"LA Valentino","year":"2023","unstructured":"Valentino LA, Ozelo MC, Herzog RW, et al. A review of the rationale for gene therapy for hemophilia\u00a0A with inhibitors: one-shot tolerance and treatment? J Thromb Haemost. 2023;21(11):3033\u201344.","journal-title":"J Thromb Haemost"},{"key":"3110_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100642","volume":"41","author":"EC Rodriguez-Merchan","year":"2020","unstructured":"Rodriguez-Merchan EC. Serological biomarkers in hemophilic arthropathy: can they be used to monitor bleeding and ongoing progression of blood-induced joint disease in patients with hemophilia? Blood Rev. 2020;41: 100642.","journal-title":"Blood Rev"},{"issue":"1","key":"3110_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2022.100020","volume":"7","author":"I Oomen","year":"2022","unstructured":"Oomen I, Camelo RM, Rezende SM, et al. Determinants of successful immune tolerance induction in hemophilia\u00a0A: systematic review and meta-analysis. Res Pract Thromb Haemost. 2022;7(1):100020.","journal-title":"Res Pract Thromb Haemost"},{"key":"3110_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100852","volume":"50","author":"E Berntorp","year":"2021","unstructured":"Berntorp E, Hermans C, Solms A, Poulsen L, Mancuso ME. Optimising prophylaxis in haemophilia\u00a0A: the ups and downs of treatment. Blood Rev. 2021;50:100852.","journal-title":"Blood Rev"},{"issue":"4","key":"3110_CR7","doi-asserted-by":"publisher","first-page":"570","DOI":"10.25122\/jml-2022-0103","volume":"15","author":"A Batorova","year":"2022","unstructured":"Batorova A, Boban A, Brinza M, et al. Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia\u00a0A. J Med Life. 2022;15(4):570\u20138.","journal-title":"J Med Life"},{"issue":"2","key":"3110_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14737167.2020.1789457","volume":"21","author":"HK Kim","year":"2021","unstructured":"Kim HK, Peral C, Rubio-Rodr\u00edguez D, Rubio-Terr\u00e9s C. Cost of patients with hemophilia\u00a0A treated with standard half-life or extended half-life FVIII in Spain. Expert Rev Pharmacoecon Outcomes Res. 2021;21(2):315\u201320.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7","key":"3110_CR9","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1111\/jth.15342","volume":"19","author":"G Young","year":"2021","unstructured":"Young G. Management of children with hemophilia\u00a0A: how emicizumab has changed the landscape. J Thromb Haemost. 2021;19(7):1629\u201337.","journal-title":"J Thromb Haemost"},{"issue":"11","key":"3110_CR10","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1007\/s00277-020-04280-3","volume":"99","author":"A Solms","year":"2020","unstructured":"Solms A, Shah A, Berntorp E, et al. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia\u00a0A. Ann Hematol. 2020;99(11):2689\u201398.","journal-title":"Ann Hematol"},{"issue":"4","key":"3110_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1358\/dot.2018.54.4.2800622","volume":"54","author":"S Raso","year":"2018","unstructured":"Raso S, Hermans C. Recombinant factor\u00a0VIII: past, present and future of treatment of hemophilia\u00a0A. Drugs Today (Barc). 2018;54(4):269\u201381.","journal-title":"Drugs Today (Barc)"},{"issue":"4","key":"3110_CR12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2209226","volume":"388","author":"A Von Drygalski","year":"2023","unstructured":"Von Drygalski A, Chowdary P, Kulkarni R, et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia\u00a0A. N Engl J Med. 2023;388(4):310\u20138.","journal-title":"N Engl J Med"},{"issue":"26","key":"3110_CR13","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1182\/blood.2021013563","volume":"139","author":"C K\u00f6nigs","year":"2022","unstructured":"K\u00f6nigs C, Ozelo MC, Dunn A, et al. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia\u00a0A: PUPs A-LONG final results. Blood. 2022;139(26):3699\u2013707.","journal-title":"Blood"},{"issue":"3","key":"3110_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1182\/blood.2019000658","volume":"134","author":"HM van den Berg","year":"2019","unstructured":"van den Berg HM, Fischer K, Carcao M, et al. Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia\u00a0A. Blood. 2019;134(3):317\u201320.","journal-title":"Blood"},{"issue":"3","key":"3110_CR15","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/hae.13747","volume":"25","author":"P Volkers","year":"2019","unstructured":"Volkers P, Hanschmann KM, Calvez T, et al. Recombinant factor\u00a0VIII products and inhibitor development in previously untreated patients with severe haemophilia\u00a0A: combined analysis of three studies. Haemophilia. 2019;25(3):398\u2013407.","journal-title":"Haemophilia"},{"key":"3110_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jclinepi.2021.08.022","volume":"140","author":"E Igelstr\u00f6m","year":"2021","unstructured":"Igelstr\u00f6m E, Campbell M, Craig P, Katikireddi SV. Cochrane\u2019s risk of bias tool for non-randomized studies (ROBINS-I) is frequently misapplied: a methodological systematic review. J Clin Epidemiol. 2021;140:22\u201332.","journal-title":"J Clin Epidemiol"},{"key":"3110_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","author":"MJ Page","year":"2020","unstructured":"Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2020. https:\/\/doi.org\/10.1136\/bmj.n160.","journal-title":"BMJ"},{"issue":"8","key":"3110_CR18","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/j.1538-7836.2008.03032.x","volume":"6","author":"VS Blanchette","year":"2008","unstructured":"Blanchette VS, Shapiro A, Liesner R, et al. Plasma and albumin-free recombinant factor\u00a0VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost. 2008;6(8):1319\u201326.","journal-title":"J Thromb Haemost"},{"issue":"06","key":"3110_CR19","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1160\/TH11-09-0642","volume":"107","author":"G Auerswald","year":"2012","unstructured":"Auerswald G, Thompson AA, Recht M, et al. Experience of advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia\u00a0A. Thromb Haemost. 2012;107(06):1072\u201382.","journal-title":"Thromb Haemost"},{"issue":"6","key":"3110_CR20","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/jth.12911","volume":"13","author":"G Young","year":"2015","unstructured":"Young G, Mahlangu J, Kulkarni R, et al. Recombinant factor\u00a0VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia\u00a0A. J Thromb Haemost. 2015;13(6):967\u201377.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"3110_CR21","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/jth.13647","volume":"15","author":"O Stasyshyn","year":"2017","unstructured":"Stasyshyn O, Khayat CD, Iosava G, et al. Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia\u00a0A: results of a multicenter clinical trial. J Thromb Haemost. 2017;15(4):636\u201344.","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"3110_CR22","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1182\/blood-2018-99-110308","volume":"132","author":"P Chowdary","year":"2018","unstructured":"Chowdary P, Poulsen LH, Escobar MA, et al. Efficacy of an extended half-life glycoPEGylated rFVIII (N8-GP): pooled analysis of ABR (results from two clinical trials). Blood. 2018;132(Suppl 1):1177.","journal-title":"Blood"},{"issue":"6","key":"3110_CR23","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/hae.13551","volume":"24","author":"M Mathias","year":"2018","unstructured":"Mathias M, Collins P, Palmer B, et al. The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia\u00a0A in the United Kingdom. Haemophilia. 2018;24(6):896\u2013901.","journal-title":"Haemophilia"},{"issue":"5","key":"3110_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/hae.14100","volume":"26","author":"CJ Jonker","year":"2020","unstructured":"Jonker CJ, Oude Rengerink K, Hoes AW, Mol PG, van den Berg HM. Inhibitor development in previously untreated patients with severe haemophilia: a comparison of included patients and outcomes between a clinical study and a registry-based study. Haemophilia. 2020;26(5):809\u201316.","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"3110_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/jth.15036","volume":"18","author":"S \u0160aulyt\u0117 Trakymien\u0117","year":"2020","unstructured":"\u0160aulyt\u0117 Trakymien\u0117 S, Economou M, Kenet G, Landorph A, Shen C, Kearney S. Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia\u00a0A: final results from pathfinder5. J Thromb Haemost. 2020;18(Suppl 1):15\u201325.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"3110_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/hae.13883","volume":"26","author":"H Yaish","year":"2020","unstructured":"Yaish H, Matsushita T, Belhani M, et al. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia\u00a0A: results from the guardian 4 multinational clinical trial. Haemophilia. 2020;26(1):64\u201372.","journal-title":"Haemophilia"},{"key":"3110_CR27","doi-asserted-by":"crossref","unstructured":"Sidonio Jr RF, Thompson AA, Peyvandi F, et al. Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia\u00a0A: interim results from a phase\u00a03, prospective, multicenter, open-label study. Expert Rev Hematol. 2023; 16(10):793\u2013801","DOI":"10.1080\/17474086.2023.2247160"},{"issue":"6","key":"3110_CR28","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1111\/hae.14622","volume":"28","author":"R Wu","year":"2022","unstructured":"Wu R, Wang X, Zhao X, et al. Efficacy, safety and pharmacokinetics of recombinant human coagulation factor\u00a0VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia\u00a0A. Haemophilia. 2022;28(6):e199\u2013208.","journal-title":"Haemophilia"},{"issue":"01","key":"3110_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1055\/s-0042-1757876","volume":"123","author":"R Ljung","year":"2023","unstructured":"Ljung R, Chan AK, Glosli H, et al. BAY\u00a081-8973 efficacy and safety in previously untreated and minimally treated children with severe hemophilia\u00a0A: the LEOPOLD kids trial. Thromb Haemost. 2023;123(01):27\u201339.","journal-title":"Thromb Haemost"},{"issue":"11","key":"3110_CR30","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1016\/j.jtha.2023.07.030","volume":"21","author":"G Kenet","year":"2023","unstructured":"Kenet G, Young G, Chuansumrit A, et al. The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia\u00a0A: pathfinder6 end-of-trial results. J Thromb Haemost. 2023;21(11):3109\u201316.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"3110_CR31","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1111\/hae.14052","volume":"26","author":"P Chowdary","year":"2020","unstructured":"Chowdary P, Mullins ES, Konkle BA, et al. Long-term safety and efficacy results from the phase\u00a03b, open-label, multicentre continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia\u00a0A. Haemophilia. 2020;26(4):e168\u201378.","journal-title":"Haemophilia"},{"issue":"6","key":"3110_CR32","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1182\/bloodadvances.2023011475","volume":"8","author":"M Carcao","year":"2024","unstructured":"Carcao M, Schiavulli M, Kulkarni R, et al. A post hoc analysis of previously untreated patients with severe hemophilia\u00a0A who developed inhibitors in the PUPs A-LONG trial. Blood Adv. 2024;8(6):1494\u2013503.","journal-title":"Blood Adv"},{"key":"3110_CR33","doi-asserted-by":"publisher","first-page":"1019275","DOI":"10.3389\/fimmu.2022.1019275","volume":"13","author":"L Luo","year":"2022","unstructured":"Luo L, Zheng Q, Chen Z, et al. Hemophilia a patients with inhibitors: mechanistic insights and novel therapeutic implications. Front Immunol. 2022;13:1019275.","journal-title":"Front Immunol"},{"key":"3110_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.05.014","author":"NH Nguyen","year":"2023","unstructured":"Nguyen NH, Jarvi NL, Balu-Iyer SV. Immunogenicity of therapeutic biological modalities-lessons from hemophilia\u00a0A therapies. J Pharmaceut Sci. 2023. https:\/\/doi.org\/10.1016\/j.xphs.2023.05.014.","journal-title":"J Pharmaceut Sci"},{"key":"3110_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14803","author":"PM Mannucci","year":"2023","unstructured":"Mannucci PM, Kessler CM, Germini F, et al. Bleeding events in people with congenital haemophilia\u00a0A without factor\u00a0VIII inhibitors receiving prophylactic factor\u00a0VIII treatment: a systematic literature review. Haemophilia. 2023. https:\/\/doi.org\/10.1111\/hae.14803.","journal-title":"Haemophilia"},{"key":"3110_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14797","author":"J Blatn\u00fd","year":"2023","unstructured":"Blatn\u00fd J, Nielsen EM, Reitzel SB, et al. Real-world evidence on efmoroctocog alfa in patients with haemophilia\u00a0A: a systematic literature review of treatment experience in Europe. Haemophilia. 2023. https:\/\/doi.org\/10.1111\/hae.14797.","journal-title":"Haemophilia"},{"key":"3110_CR37","doi-asserted-by":"crossref","unstructured":"Witarto BS, Visuddho V, Witarto AP, Sutanto H, Wiratama BS, Wungu CDK. Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia\u00a0A: a systematic review and meta-analysis of clinical trials. F1000Res. 2021;10:1049.","DOI":"10.12688\/f1000research.73884.2"},{"issue":"12","key":"3110_CR38","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1080\/13696998.2020.1828092","volume":"23","author":"L Graf","year":"2020","unstructured":"Graf L, Yan S, Shen M-C, Balasa V. A systematic review evaluating the efficacy and factor consumption of long-acting recombinant factor\u00a0VIII products for the prophylactic treatment of hemophilia\u00a0A. J Med Econ. 2020;23(12):1493\u20138.","journal-title":"J Med Econ"},{"issue":"3","key":"3110_CR39","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1517\/14712590902729392","volume":"9","author":"A Shapiro","year":"2009","unstructured":"Shapiro A, Gruppo R, Pabinger I, et al. Integrated analysis of safety and efficacy of a plasma-and albumin-free recombinant factor\u00a0VIII (rAHF-PFM) from six clinical studies in patients with hemophilia\u00a0A. Expert Opin Biol Ther. 2009;9(3):273\u201383.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"3110_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/17474086.2018.1419862","volume":"11","author":"E Santagostino","year":"2018","unstructured":"Santagostino E, Young G, Carcao M, Mannucci PM, Halimeh S, Austin S. A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies. Expert Rev Hematol. 2018;11(2):87\u201397.","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"3110_CR41","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2020.001","volume":"12","author":"P Tieu","year":"2020","unstructured":"Tieu P, Chan A, Matino D. Molecular mechanisms of inhibitor development in hemophilia. Mediterr J Hematol Infect Dis. 2020;12(1):e2020001.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"212\u2013219","key":"3110_CR42","volume":"234","author":"P Saultier","year":"2021","unstructured":"Saultier P, Guillaume Y, Demiguel V, et al. Compliance with early long-term prophylaxis guidelines for severe hemophilia\u00a0A. J Pediatr. 2021;234(212\u2013219):e213.","journal-title":"J Pediatr"},{"key":"3110_CR43","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3389\/fimmu.2020.00563","volume":"11","author":"A Abdi","year":"2020","unstructured":"Abdi A, Bordbar M, Hassan S, et al. Prevalence and incidence of non-neutralizing antibodies in congenital hemophilia a\u2014a systematic review and meta-analysis. Front Immunol. 2020;11:563.","journal-title":"Front Immunol"},{"issue":"6","key":"3110_CR44","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/jth.14124","volume":"16","author":"S Hassan","year":"2018","unstructured":"Hassan S, Cannav\u00f2 A, Gouw S, Rosendaal FR, van der Bom J. Factor\u00a0VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia\u00a0A: a systematic review. J Thromb Haemost. 2018;16(6):1055\u201368.","journal-title":"J Thromb Haemost"},{"issue":"22","key":"3110_CR45","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1182\/bloodadvances.2020002731","volume":"4","author":"B Reipert","year":"2020","unstructured":"Reipert B, Gangadharan B, Hofbauer C, et al. The prospective hemophilia inhibitor PUP study reveals distinct antibody signatures prior to FVIII inhibitor development. Blood Adv. 2020;4(22):5785\u201396.","journal-title":"Blood Adv"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03110-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03110-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03110-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T06:50:53Z","timestamp":1744872653000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03110-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3110"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03110-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"27 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xiaoqin Feng, Xuan Zhou, Jing Sun have received no compensation or remuneration for their contribution to the writing of this manuscript or its appendices. Zhenguo Wang is currently employed by Takeda (China) International Trade Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}